Perspective Therapeutics Announces Collaboration Agreement Qith Bristol Myers Squibb To Evaluate [(212)Pb]VMT01 In Combination With Nivolumab In MC1R-Positive Metastatic Melanoma; Perspective Will Sponsor And Fund The Combination Study And Bristol Myers Squibb Will Provide Nivolumab For Use In The Study.

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!